



2Q16 AND 1H16 EARNINGS CALL

DISCLAIMER




This presentation brings statements about future events that are subject to risks and uncertainties. Such statements are based on our Management's beliefs and assumptions and on information that the Company currently has access to. Statements about future events include information regarding our intentions, beliefs or current expectations, as well as those of the members of the Management Board and Company Directors.

Disclaimers according to the statements and the information about the future also include information about possible or presumed operating results, as well as statements preceded by, followed by or that include the words "believes", "may", "will", "continue", "expects", "anticipates", "intends", "plans", "estimates" or similar expressions.

The statements and information are not guarantees of future performance. They involve risks, uncertainties and assumptions because they are related to future events and, therefore, depending on circumstances that may or may not occur. Future results and value creation for our shareholders may differ materially from those expressed or implied by the statements made about the future. Many of the factors that will determine these results and values are beyond our ability to control or predict.

TOTAL NET REVENUE


Ourofino Saúde Animal (R\$ million)



NET REVENUE BY SEGMENT


Production Animals

Net Revenue – (R\$ million)




Companion Animals

Net Revenue – (R\$ million)



International Operations


Net Revenue – (R\$ million)




FINANCIAL PERFORMANCE



Gross Profit (R\$ million)




SG&A (R\$ million)



— Percentage over net revenue



Adjusted EBITDA (R\$ million)




FINANCIAL PERFORMANCE




Net Financial Expense

(R\$ million)




Tax Expenses

(R\$ million)



Net Profit

(R\$ million)




— Profit margin

INDEBTEDNESS



Net Debt and Equity (R\$ million)



Net Debt.¹ / Adjusted EBITDA

1.63x


2.06x

Average interest on debt in 30/06¹

5.75%

9.52%

Debt Aging² (R\$ million)




- Cash and equivalents of R\$ 23.2 million.

Note 1: Average cost calculated on the debt netted of derivatives.

Note 2: Aging is for gross debt



R&D Investment (R\$ million)



Launched products



■ Intangible assets
 ■ Results
 ● % Net Revenue



1H16 Launches

2nd quarter



Evol

Broad-spectrum endectocide for cattle; its formulation is based on ivermectin and albendazole sulfoxide

Category

Endectocide
(Production animals)



Nulli

Tramadol-based oral analgesic for dogs and cats

Category

Therapeutic product
(Companion Animals)

1st quarter



Resolutor

Antibiotic prescribed for the quick treatment of respiratory diseases in animals

Category

Antimicrobial
(Production animals)




Ourovac Raiva

Vaccine against rabies in cattle


Category

Biological
(Production animals)

SHARE RETURN VS IBOVESPA*



*Dividends are included in the return



Net Revenue: Revenue growth for companion animals and international operations. Production animals good performance, isolating effects from foot and mouth disease vaccine and poultry and swine products



Launches: 4 products in the 1H16



Biological Plant: in line with schedule. Production is to start by the beginning of 2017